Purpose
=======

Tyrosine kinase inhibitors (TKIs) have improved overall survival of patients with chronic myeloid leukemia (CML). Moreover, it has been reported that some of the patients achieve treatment-free remission (TFR) after cessation of TKIs, even though leukemic stem cells (LSC) of CML are considered to be resistant to TKIs. Therefore, these findings suggest that remaining LSCs could be eradicated by immune system after withdrawal of TKIs. In order to clarify the role of anti-LSC immunity in achieving TFR, we tried to detect cytotoxic T cells against one of the LSC antigens, KU-MEL9 in CML patients.

Methods
=======

Fresh blood samples were obtained from 16 CML patients who stopped imatinib after maintained complete molecular response (CMR) for more than two years at 0,3, and 6 months after cessation of imatinib. Mononuclear cells were stimulated with LSC antigen, KU-MEL9-derived nanomer peptide twice *in vitro*, then stained with anti-KU-MEL9-specific dextramer and analyzed by flow cytometry. Immunophenotype of lymphocytes was also determined by flow cytometry.

Results
=======

We detected KU-MEL9-specific CTLs in 3 of 16 patients (Table [1](#T1){ref-type="table"}). All of these patients remained in CMR at least 12 months after cessation of imatinib. On the other hand, none of 4 patients who showed molecular relapse presented with KU-MEL9-specific CTLs. The relapse rate of patients without KU-MEL9-CTLs was 31.3%, as compared to 0 % in KU-MEL9-CTL-positive patients. Percentage of CD4^+^ CD25^+^ cells was higher in patients who experienced loss of CMR.

  Patients   0m   3m   6m   Clinical course
  ---------- ---- ---- ---- -------------------
  1          \-   \-   \-   Molecular relapse
  2          \-   \-   \-   CMR
  3          \-   \-   \+   CMR
  4          \-   \-   \-   CMR
  5          \-   \-   \-   CMR
  6          \-   \+   \-   CMR
  7          \-   \-   \-   CMR
  8          \-   \-   \-   Molecular relapse
  9          \-   \-   \-   CMR
  10         \-   \-   \-   CMR
  11         \-   \-   \-   Molecular relapse
  12         \-   \-   \-   Molecular relapse
  13         \-   \-   \-   CMR
  14         \+   \-   \-   CMR
  15         \-   \-   \-   CMR
  16         \-   \-   \-   CMR

Conclusion
==========

We found LSC antigen-specific T cells only in patients who achieved TFR. Although the patient size is small, these data suggest that anti-LSC CTLs may play a role in eradicating remaining LSCs after imatinib treatment and LSC antigen-specific immunotherapy could be useful to increase TFR rate.

Consent
=======

Written informed consent was obtained from the patients for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
